What is GeneMe?
GeneMe operates within the specialized field of genetic laboratory diagnostics, providing advanced qPCR diagnostic kits tailored for professionals. The company distinguishes itself through its rapid development capabilities, able to create new genetic tests in as little as four weeks, leveraging proprietary technology. Its core offerings are designed to enhance the accuracy and efficiency of genetic analysis, serving critical areas such as single nucleotide polymorphisms (SNPs), sexually transmitted infections (STIs), and broader infectious diseases. GeneMe's commitment is to deliver cutting-edge genetic testing solutions to healthcare providers, aiming to improve diagnostic outcomes and streamline laboratory workflows.
How much funding has GeneMe raised?
GeneMe has raised a total of $6.4M across 1 funding round:
Angel/Seed
$6.4M
Angel/Seed (2020): $6.4M with participation from Robin Tombs
Key Investors in GeneMe
Robin Tombs
Robin Tombs is an early-stage investor participating in this funding round. Given the lack of domain information, their specific investment focus remains undisclosed but suggests a belief in GeneMe's foundational potential.
What's next for GeneMe?
The substantial enterprise-level funding and recent strategic investment indicate GeneMe is poised for significant scaling and market expansion. This capital infusion will likely fuel further research and development, enabling the company to broaden its portfolio of genetic tests and enhance its patented technology. GeneMe's strategic focus on rapid test development and its application in high-demand areas like infectious diseases positions it for accelerated growth. Future endeavors may include expanding its professional client base, forging strategic partnerships within the healthcare ecosystem, and potentially exploring new diagnostic applications for its innovative platform.
See full GeneMe company page
